NEW YORK, July 20, 2017 (GLOBE NEWSWIRE) -- Calyxt (Nasdaq:CLXT), a consumer-centric, food- and agriculture-focused company,
visited the Nasdaq MarketSite in Times Square today in celebration of its initial public offering (IPO) on The Nasdaq Stock Market.
Photos accompanying this announcement are available at
http://www.globenewswire.com/NewsRoom/AttachmentNg/4d4663f1-9ea8-49ec-8f8e-fe7b0f8308e6
http://www.globenewswire.com/NewsRoom/AttachmentNg/43493e68-16d9-4217-9db0-b60825368e65
Calyxt seeks to bridge the divide between evolving consumer preferences and the historical approach by the large legacy
companies in the agriculture supply chain. By combining its leading gene editing technology and technical expertise with its
innovative commercial strategy, Calyxt is pioneering a paradigm shift to deliver healthier specialty food ingredients for consumers
and agriculturally advantageous crop traits to farmers.
“As more and more food companies are looking for specialty ingredients that can help them to satisfy customers’ evolving needs
and desire to lead healthier lifestyles, Calyxt is perfectly positioned to be an industry leader with the emergence of gene editing
as a truly game-changing technology in the food space,” said Federico Tripodi, CEO, Calyxt. “Coupled with our innovative commercial
strategy, this will allow Calyxt to meet the needs of today’s consumer preferences – all of the while helping to shape the
landscape for the future of food as we know it.”
“Calyxt believes that the precision, specificity, cost-effectiveness and development speed of the company’s gene editing
technologies will enable it to provide meaningful disruption to the food and agriculture industries. We are proud to welcome Calyxt
to the Nasdaq family of innovators,” said Nelson Griggs, Executive Vice President, Head of Global Listings, Nasdaq.
The information contained above is provided for informational and educational purposes only, and nothing contained herein
should be construed as investment advice, either on behalf of a particular security or an overall investment strategy. Information
about the company is provided by the company or comes from the company’s public filings and is not independently verified by
Nasdaq. Neither Nasdaq nor any of its affiliates makes any recommendation to buy or sell any security or any representation
about the financial condition of any company. Statements regarding Nasdaq-listed companies are not guarantees of future
performance. Actual results may differ materially from those expressed or implied. Past performance is not indicative of future
results. Investors should undertake their own due diligence and carefully evaluate companies before investing. ADVICE FROM A
SECURITIES PROFESSIONAL IS STRONGLY ADVISED.
About Nasdaq
Nasdaq (Nasdaq:NDAQ) is a leading global provider of trading, clearing, exchange technology, listing, information and
public company services. Through its diverse portfolio of solutions, Nasdaq enables customers to plan, optimize and execute their
business vision with confidence, using proven technologies that provide transparency and insight for navigating today's global
capital markets. As the creator of the world's first electronic stock market, its technology powers more than 90 marketplaces in 50
countries, and 1 in 10 of the world's securities transactions. Nasdaq is home to 3,800 total listings with a market value of $11
trillion. To learn more, visit: http://business.nasdaq.com
About Calyxt
Calyxt, Inc. is a consumer-centric, food- and agriculture-focused company. By combining its leading gene-editing
technology and technical expertise with its innovative commercial strategy, Calyxt is pioneering a paradigm shift to deliver
healthier food ingredients, such as healthier oils and high fiber wheat, for consumers and agriculturally advantageous crop traits,
such as herbicide tolerance, for farmers. Calyxt is located in Minneapolis-St. Paul, Minn., and is a wholly owned subsidiary of
Cellectis.
For further information please visit our website: www.calyxt.com
Calyxt™ and the corporate logo are trademarks owned by Calyxt, Inc.
Talking about gene editing? We do it.
TALEN® is a registered trademark owned by the Cellectis Group.
- NDAQG -
Media Relations Contacts: Stephanie Lowenthal (646) 441-5073 Stephanie.Lowenthal@nasdaq.com Emily Pan (646) 441-5120 emily.pan@nasdaq.com Caitlin Kasunich / Nick Opich KCSA Strategic Communications 212.896.1241 / 212.896.1206 ckasunich@kcsa.com / nopich@kcsa.com
